{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:17:32Z","timestamp":1788545852164,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000308","name":"British Council's Higher Education","doi-asserted-by":"publisher","award":["SP-360"],"award-info":[{"award-number":["SP-360"]}],"id":[{"id":"10.13039\/501100000308","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Parasitology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.exppara.2015.04.017","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T18:20:37Z","timestamp":1429640437000},"page":"93-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs"],"prefix":"10.1016","volume":"154","author":[{"given":"Qaisar","family":"Jamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazma Habib","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Wahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahwish Mustafa","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.exppara.2015.04.017_bib0010","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00436-011-2555-5","article-title":"Leishmania antimony resistance: what we know what we can learn from the field","volume":"109","author":"A\u00eft-Oudhia","year":"2011","journal-title":"Parasitol. Res"},{"issue":"5","key":"10.1016\/j.exppara.2015.04.017_bib0015","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.exppara.2015.04.017_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2007.08.003","article-title":"Mucosal leishmaniasis current scenario and prospects for treatment","volume":"105","author":"Amato","year":"2008","journal-title":"Acta Trop"},{"key":"10.1016\/j.exppara.2015.04.017_bib0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejmech.2013.02.024","article-title":"Discovery of 3,3\u2032-diindolylmethanes as potent antileishmanial agents","volume":"63","author":"Bharate","year":"2013","journal-title":"Eur. J. Med. Chem"},{"key":"10.1016\/j.exppara.2015.04.017_bib0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1086\/515174","article-title":"Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis","volume":"28","author":"Burman","year":"1999","journal-title":"Clin. Infect. Dis"},{"key":"10.1016\/j.exppara.2015.04.017_bib0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.trstmh.2006.03.009","article-title":"Miltefosine \u2013 discovery of the antileishmanial activity of phospholipid derivatives","volume":"100","author":"Croft","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg"},{"key":"10.1016\/j.exppara.2015.04.017_bib0040","first-page":"399","article-title":"Current scenario of drug development for Leishmaniasis","volume":"123","author":"Croft","year":"2006","journal-title":"Indian J. Med. Res"},{"issue":"7","key":"10.1016\/j.exppara.2015.04.017_bib0045","doi-asserted-by":"crossref","first-page":"e1253","DOI":"10.1371\/journal.pntd.0001253","article-title":"A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit","volume":"5","author":"De Muylder","year":"2011","journal-title":"PLoS Negl. Trop. Dis"},{"key":"10.1016\/j.exppara.2015.04.017_bib0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp. Immunol. Microbiol. Infect. Dis"},{"key":"10.1016\/j.exppara.2015.04.017_bib0055","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijpara.2012.02.015","article-title":"Giardia lamblia: a new target for miltefosine","volume":"42","author":"Eissa","year":"2012","journal-title":"Int. J. Parasitol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ajme.2012.04.003","article-title":"Miltefosine for old world cutaneous leishmaniasis: an experimental study on Leishmania major infected mice","volume":"48","author":"Eissa","year":"2012","journal-title":"Alex. J. Med"},{"key":"10.1016\/j.exppara.2015.04.017_bib0065","first-page":"11","article-title":"Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it?","volume":"2","author":"Freitas-Junior","year":"2012","journal-title":"Int. J. Parasitol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0070","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.exppara.2012.03.021","article-title":"Validation of quantitative real-time PCR for the in vitro assessment of antileishmanial drug activity","volume":"131","author":"Gomes","year":"2012","journal-title":"Exp. Parasitol"},{"issue":"2","key":"10.1016\/j.exppara.2015.04.017_bib0075","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4269\/ajtmh.11-0812","article-title":"Drug discovery algorithm for cutaneous leishmaniasis","volume":"88","author":"Grogl","year":"2013","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"10.1016\/j.exppara.2015.04.017_bib0080","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.etap.2012.01.005","article-title":"Study on cytotoxicity and structure\u2013activity relationship of HL-7702 cell exposed to naphthoquinones","volume":"33","author":"Guo","year":"2012","journal-title":"Environ. Toxicol. Pharmacol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0085","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00436-007-0638-0","article-title":"Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs","volume":"101","author":"Hadighi","year":"2007","journal-title":"Parasitol. Res"},{"key":"10.1016\/j.exppara.2015.04.017_bib0090","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1016\/j.ejmech.2010.04.004","article-title":"Synthesis of 2-(pyrimidin-2-yl)-1-phenyl-2,3,4,9 tetrahydro-1H-b-carbolinesas antileishmanial agents","volume":"45","author":"Kumar","year":"2010","journal-title":"Eur. J. Med. Chem"},{"issue":"4","key":"10.1016\/j.exppara.2015.04.017_bib0095","first-page":"737","article-title":"In-vitro antioxidant activity of methanolic extract in leaves of Anisomeles malabarica Linn","volume":"1","author":"Lavanya","year":"2010","journal-title":"Res. J. Pharm. Biol. Chem. Sci"},{"key":"10.1016\/j.exppara.2015.04.017_bib0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bionut.2011.06.012","article-title":"In vitro antileishmanial properties of new flavonoids against Leishmania donovani","volume":"1","author":"Lewin","year":"2011","journal-title":"Biomed. Prev. Nutr"},{"issue":"6","key":"10.1016\/j.exppara.2015.04.017_bib0105","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2009.03.004","article-title":"Tropical dermatology: tropical diseases caused by protozoa","volume":"60","author":"Lupi","year":"2009","journal-title":"J. Am. Acad. Dermatol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0110","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jconrel.2012.05.023","article-title":"Defeating Leishmania resistance to Miltefosine (hexadecylphosphocholine) bypeptide-mediated drug smuggling: a proof of mechanism for trypanosomatid chemotherapy","volume":"161","author":"Luque-Ortega","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.exppara.2015.04.017_bib0115","series-title":"Drug Resistance in Leishmania Parasites: Consequences, Molecular Mechanisms and Possible Treatments","first-page":"407","article-title":"The relevance of susceptibility tests, breakpoints, and markers","author":"Maes","year":"2013"},{"issue":"1","key":"10.1016\/j.exppara.2015.04.017_bib0120","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1021\/jm030868a","article-title":"Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone","volume":"47","author":"M\u00e4ntyl\u00e4","year":"2004","journal-title":"J. Med. Chem"},{"key":"10.1016\/j.exppara.2015.04.017_bib0125","series-title":"GraphPad Prism Version 4.0","author":"Miller","year":"2003"},{"key":"10.1016\/j.exppara.2015.04.017_bib0130","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.intimp.2011.05.008","article-title":"Vaccine candidates for leishmaniasis: a review","volume":"11","author":"Nagill","year":"2011","journal-title":"Int. Immunopharmacol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0135","first-page":"114","article-title":"Cutaneous Leishmaniasis in Sadda, Kurram agency, Pakistan","volume":"14","author":"Noor","year":"2004","journal-title":"J. Pak. Assoc. Dermatol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0140","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1128\/JCM.36.10.2877-2881.1998","article-title":"A nested-PCR-based schizodeme method for identifying Leishmania kinetoplast minicircle classes directly from clinical samples and its application to the study of the epidemiology of Leishmania tropica in Pakistan","volume":"36","author":"Noyes","year":"1998","journal-title":"J. Clin. Microbiol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jep.2009.07.015","article-title":"Ta'ta', Huayani: perception of leishmaniasis and evaluation of medicinal plants used by the Chayahuita in Peru. Part II","volume":"126","author":"Odonne","year":"2009","journal-title":"J. Ethnopharmacol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World","volume":"118","author":"Oliveira","year":"2011","journal-title":"Acta Trop"},{"key":"10.1016\/j.exppara.2015.04.017_bib9010","first-page":"75","article-title":"Discovery of a new antileishmanial hit in 8-nitroquinoline series. Euro","volume":"54","author":"Paloque","year":"2012","journal-title":"Jour. Med. Chem"},{"key":"10.1016\/j.exppara.2015.04.017_bib0160","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2006.04.001","article-title":"Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use","volume":"9","author":"P\u00e9rez-Victoria","year":"2006","journal-title":"Drug Resist. Updat"},{"issue":"2","key":"10.1016\/j.exppara.2015.04.017_bib0165","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1128\/AAC.00030-11","article-title":"Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"56","author":"Purkait","year":"2012","journal-title":"Antimicrob. Agents Chemother"},{"issue":"6","key":"10.1016\/j.exppara.2015.04.017_bib0170","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00284-012-0209-1","article-title":"Development of luciferase expressing Leishmania donovani axenic amastigotes as primary model for in vitro screening of antileishmanial compounds","volume":"65","author":"Ravinder","year":"2012","journal-title":"Curr. Microbiol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.exppara.2012.01.010","article-title":"Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi","volume":"130","author":"Reim\u00e3o","year":"2012","journal-title":"Exp. Parasitol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/JCM.02029-06","article-title":"Molecular diagnosis of leishmaniasis: current status and future applications","volume":"45","author":"Reithinger","year":"2007","journal-title":"J. Clin. Microbiol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0035-9203(99)90285-7","article-title":"An outbreak of cutaneous leishmaniasis in an Afghan refugee settlement in north-west Pakistan","volume":"93","author":"Rowland","year":"1999","journal-title":"Trans. R. Soc. Trop. Med. Hyg"},{"issue":"1","key":"10.1016\/j.exppara.2015.04.017_bib0190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/AAC.50.1.73-79.2006","article-title":"In vitro and in vivo interactions between miltefosine and other antileishmanial drugs","volume":"50","author":"Seifert","year":"2006","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.exppara.2015.04.017_bib0195","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2007.05.007","article-title":"Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo","volume":"30","author":"Seifert","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.exppara.2015.04.017_bib0200","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00436-011-2599-6","article-title":"The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate","volume":"110","author":"Shakori","year":"2012","journal-title":"Parasitol. Res"},{"key":"10.1016\/j.exppara.2015.04.017_bib0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00430-003-0201-2","article-title":"Miltefosine (Impavido): the first oral treatment against leishmaniasis","volume":"193","author":"Sindermann","year":"2004","journal-title":"Med. Microbiol. Immunol."},{"issue":"6","key":"10.1016\/j.exppara.2015.04.017_bib0210","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","article-title":"Leishmaniasis: current status of available drugs and new potential drug targets","volume":"5","author":"Singh","year":"2012","journal-title":"Asian Pac. J. Trop. Med"},{"key":"10.1016\/j.exppara.2015.04.017_bib0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/0975-7406.124309","article-title":"Buparvaquone loaded solid lipid nanoparticles for targeted delivery in theleriosis","volume":"6","author":"Soni","year":"2014","journal-title":"J. Pharm. Bioallied Sci"},{"key":"10.1016\/j.exppara.2015.04.017_bib0220","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.exppara.2010.05.016","article-title":"Leishmania tarentolae: utility as an in vitro model for screening of antileishmanial agents","volume":"126","author":"Taylor","year":"2010","journal-title":"Exp. Parasitol"},{"issue":"4","key":"10.1016\/j.exppara.2015.04.017_bib0225","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jpba.2006.11.013","article-title":"Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies","volume":"43","author":"Venkatesh","year":"2007","journal-title":"J. Pharm. Biomed. Anal"},{"issue":"5","key":"10.1016\/j.exppara.2015.04.017_bib0230","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/bmc.965","article-title":"Optimization and validation of RP-HPLC-UV method with solid-phase extraction for determination of buparvaquone in human and rabbit plasma: application to pharmacokinetic study","volume":"22","author":"Venkatesh","year":"2008","journal-title":"Biomed. Chromatogr"},{"issue":"1","key":"10.1016\/j.exppara.2015.04.017_bib0235","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-4017(96)01150-8","article-title":"Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniasis","volume":"77","author":"Vexenat","year":"1998","journal-title":"Vet. Parasitol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0240","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.molbiopara.2012.03.002","article-title":"Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis","volume":"183","author":"Walker","year":"2012","journal-title":"Mol. Biochem. Parasitol"},{"key":"10.1016\/j.exppara.2015.04.017_bib0245","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1086\/507710","article-title":"American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility?","volume":"194","author":"Yardley","year":"2006","journal-title":"J. Infect. Dis"},{"issue":"12","key":"10.1016\/j.exppara.2015.04.017_bib0250","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1128\/AAC.00985-10","article-title":"Antileishmanial and anti-trypanosomal activities of the 8-aminoquinoline tafenoquine","volume":"54","author":"Yardley","year":"2010","journal-title":"Antimicrob. Agents Chemother"}],"container-title":["Experimental Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448941500106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448941500106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T04:28:47Z","timestamp":1598934527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448941500106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":49,"alternative-id":["S001448941500106X"],"URL":"https:\/\/doi.org\/10.1016\/j.exppara.2015.04.017","relation":{},"ISSN":["0014-4894"],"issn-type":[{"value":"0014-4894","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs","name":"articletitle","label":"Article Title"},{"value":"Experimental Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exppara.2015.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}